Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice
Inflammatory bowel disease (IBD) comprises ulcerative colitis (UC) and Crohn’s disease (CD). IBD etiopathology is multifactorial and involves alteration of immune cells and chronic activation of the inflammatory cascade against yet unknown environmental factors that trigger the disease. IBD therapy...
Main Authors: | Stefano Bruscoli, Marta Febo, Carlo Riccardi, Graziella Migliorati |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.691480/full |
Similar Items
-
Anti-Inflammatory Effects of Synthetic Peptides Based on Glucocorticoid-Induced Leucine Zipper (GILZ) Protein for the Treatment of Inflammatory Bowel Diseases (IBDs)
by: Musetta Paglialunga, et al.
Published: (2023-09-01) -
Glucocorticoid-Induced Leucine Zipper: A Novel Anti-inflammatory Molecule
by: Oxana Bereshchenko, et al.
Published: (2019-03-01) -
GILZ as a mediator of the anti-inflammatory effects of glucocorticoids
by: Simona eRonchetti, et al.
Published: (2015-11-01) -
Association of GILZ with MUC2, TLR2, and TLR4 in Inflammatory Bowel Disease
by: Luigi Cari, et al.
Published: (2023-01-01) -
GILZ as a Regulator of Cell Fate and Inflammation
by: Stefano Bruscoli, et al.
Published: (2021-12-01)